N. Perico, A. Benigni, G. Remuzzi (2008)
Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotectionNature Reviews Drug Discovery, 7
P. Rossing, E. Hommel, U. Smidt, H. Parving (1994)
Reduction in albuminuria predicts diminished progression in diabetic nephropathy.Kidney international. Supplement, 45
F. Holtkamp, D. Zeeuw, P. Graeff, G. Laverman, T. Berl, G. Remuzzi, D. Packham, J. Lewis, H. Parving, H. Heerspink (2011)
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.European heart journal, 32 12
B. Brenner (2002)
Remission of renal disease: recounting the challenge, acquiring the goal.The Journal of clinical investigation, 110 12
R. Zatz, B. Dunn, T. Meyer, S. Anderson, H. Rennke, B. Brenner (1986)
Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.The Journal of clinical investigation, 77 6
P. Ruggenenti, A. Perna, M. Tonelli, G. Loriga, N. Motterlini, N. Rubis, F. Ledda, S. Rota, A. Satta, A. Granata, G. Battaglia, F. Cambareri, Salvatore David, F. Gaspari, N. Stucchi, S. Carminati, B. Ene-Iordache, P. Cravedi, G. Remuzzi (2010)
Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.Clinical journal of the American Society of Nephrology : CJASN, 5 11
D. Macconi, F. Sangalli, M. Bonomelli, S. Conti, L. Condorelli, E. Gagliardini, G. Remuzzi, A. Remuzzi (2009)
Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition.The American journal of pathology, 174 3
P. Cravedi, G. Remuzzi, P. Ruggenenti (2011)
Targeting the Renin Angiotensin System in Dialysis PatientsSeminars in Dialysis, 24
Upadhyay (2011)
Systematic review: Blood pressure target in chronic kidney disease and proteinuria as an effect modifier.Ann Intern Med, 154
J. Mann, D. Green, K. Jamerson, L. Ruilope, Susan Kuranoff, T. Littke, G. Viberti (2010)
Avosentan for overt diabetic nephropathy.Journal of the American Society of Nephrology : JASN, 21 3
A. Fogo, Y. Yoshida, A. Glick, T. Homma, I. Ichikawa (1988)
Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis.The Journal of clinical investigation, 82 1
Oliver (1954)
Cellular mechanisms of protein metabolism in the nephron. I. The structural aspects of proteinuria; tubular absorption, droplet formation, and the disposal of proteins.J Exp Med, 99
H. Haller, S. Ito, J. Izzo, A. Januszewicz, S. Katayamá, J. Menne, A. Mimran, T. Rabelink, E. Ritz, L. Ruilope, L. Rump, G. Viberti (2011)
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.The New England journal of medicine, 364 10
Youhua Liu (2010)
New insights into epithelial-mesenchymal transition in kidney fibrosis.Journal of the American Society of Nephrology : JASN, 21 2
E. Imai, J. Chan, S. Ito, T. Yamasaki, F. Kobayashi, M. Haneda, H. Makino, F. investigators (2011)
Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled studyDiabetologia, 54
M. Abbate, C. Zoja, G. Remuzzi (2006)
How does proteinuria cause progressive renal damage?Journal of the American Society of Nephrology : JASN, 17 11
C. Adarkwah, S. Evers, Maren Akkerman, A. Gandjour (2011)
PDB46 Cost-Effectiveness of Angiotensin Converting Enzyme Inhibitors for the Prevention of Diabetic Nephropathy in the Netherlands - A Markov ModelValue in Health, 14
F. Mallamaci, P. Ruggenenti, A. Perna, D. Leonardis, R. Tripepi, G. Tripepi, G. Remuzzi, C. Zoccali (2011)
ACE inhibition is renoprotective among obese patients with proteinuria.Journal of the American Society of Nephrology : JASN, 22 6
D. Zeeuw, R. Agarwal, M. Amdahl, P. Audhya, D. Coyne, T. Garimella, H. Parving, Y. Pritchett, G. Remuzzi, E. Ritz, D. Andress (2010)
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trialThe Lancet, 376
(2008)
Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases: Prevent and Control Cardiovascular Diseases, Cancer, Chronic Respiratory Diseases and Diabetes
(1914)
Fahr TH: Die Bright’sche Nierenkrankheit, Germany, Julius
Pfeffer (2009)
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.N Engl J Med, 361
B. Brenner, M. Cooper, D. Zeeuw, W. Keane, W. Mitch, H. Parving, G. Remuzzi, S. Snapinn, Zhonxin Zhang, S. Shahinfar (2001)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.The New England journal of medicine, 345 12
P. Ruggenenti, A. Perna, L. Mosconi, R. Pisoni, G. Remuzzi (1998)
Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).Kidney international, 53 5
E. Gagliardini, Simona Buelli, A. Benigni (2011)
Endothelin in chronic proteinuric kidney disease.Contributions to nephrology, 172
F. Hou, D. Xie, Xun Zhang, Ping-yan Chen, Wei Zhang, M. Liang, Zhi-jian Guo, Jian-ping Jiang (2007)
Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.Journal of the American Society of Nephrology : JASN, 18 6
P. Ruggenenti, E. Perticucci, P. Cravedi, V. Gambara, M. Costantini, Sanjib Sharma, A. Perna, G. Remuzzi (2008)
Role of remission clinics in the longitudinal treatment of CKD.Journal of the American Society of Nephrology : JASN, 19 6
Homer Smith (2003)
Nephron adaptation to renal injury or ablation
Goodhart (1890)
Two clinical lectures on albuminuria.BMJ, 1
D. Kohan, Y. Pritchett, M. Molitch, Shihua Wen, T. Garimella, P. Audhya, D. Andress (2011)
Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.Journal of the American Society of Nephrology : JASN, 22 4
A. Chrysostomou, G. Becker (2001)
Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease.The New England journal of medicine, 345 12
D. Zeeuw, G. Remuzzi, H. Parving, W. Keane, Zhongxin Zhang, S. Shahinfar, S. Snapinn, M. Cooper, W. Mitch, B. Brenner (2004)
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.Kidney international, 65 6
Björck (1992)
Renal protective effect of enalapril in diabetic nephropathy.BMJ, 304
A. Chanutin, E. Ferris (1932)
EXPERIMENTAL RENAL INSUFFICIENCY PRODUCED BY PARTIAL NEPHRECTOMY: I. CONTROL DIETJAMA Internal Medicine, 49
T. Addis (1948)
Glomerular nephritis : diagnosis and treatment
Pergola (2011)
Bardoxolone methyl and kidney function in CKD with type 2 diabetes.N Engl J Med, 365
H. Parving, F. Persson, J. Lewis, E. Lewis, N. Hollenberg (2008)
Aliskiren combined with losartan in type 2 diabetes and nephropathy.The New England journal of medicine, 358 23
J. Barnes, Y. Gorin (2011)
Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases.Kidney international, 79 9
A. Remuzzi, N. Perico, C. Amuchastegui, B. Malanchini, M. Mazerska, C. Battaglia, T. Bertani, G. Remuzzi (1993)
Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes.Journal of the American Society of Nephrology : JASN, 4 1
T. Hostetter, J. Olson, H. Rennke, M. Venkatachalam, B. Brenner (1981)
Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation.The American journal of physiology, 241 1
P. Ruggenenti, A. Schieppati, G. Remuzzi (2001)
Progression, remission, regression of chronic renal diseasesThe Lancet, 357
L. Hunsicker, R. Atkins, J. Lewis, G. Braden, P. Crespigny, G. Deferrari, P. Drury, F. Locatelli, T. Wiegmann, E. Lewis (2004)
Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial.Kidney international. Supplement, 92
J. Wright, G. Bakris, T. Greene (2003)
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trialAcc Current Journal Review, 12
P. Ruggenenti, A. Perna, Giulia Gherardi, G. Garini, Carmine Zoccali, M. Salvadori, F. Scolari, F. Schena, G. Remuzzi (1999)
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuriaThe Lancet, 354
Go (2004)
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.N Engl J Med, 351
J. Goodhart (1890)
Two Clinical Lectures on AlbuminuriaBritish Medical Journal, 1
L. Dworkin, T. Hostetter, H. Rennke, B. Brenner (1984)
Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension.The Journal of clinical investigation, 73 5
A. Lamy, Xiaoyin Wang, P. Gao, W. Tong, A. Gafni, A. Dans, Á. Avezum, Rafael Ferreira, James Young, S. Yusuf, K. Teo (2011)
The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET studyJournal of Medical Economics, 14
Endrik, Ehnert, Ens, Röchner, M. -, Ortensen, Amon, J Omis, Teen, Ndersen, Eter, Rner (2001)
THE EFFECT OF IRBESARTAN ON THE DEVELOPMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE 2 DIABETES
D. Kent, T. Jafar, R. Hayward, H. Tighiouart, M. Landa, P. Jong, D. Zeeuw, G. Remuzzi, A. Kamper, A. Levey (2007)
Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease.Journal of the American Society of Nephrology : JASN, 18 6
P. Ruggenenti, A. Perna, Giulia Gherardi, F. Gaspari, R. Benini, G. Remuzzi (1998)
Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trialThe Lancet, 352
H. Parving, Hendrik Lehnert, J. Bröchner-Mortensen, R. Gomis, S. Andersen, P. Arner (2001)
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.The New England journal of medicine, 345 12
A. Barnett, S. Bain, P. Bouter, B. Karlberg, S. Madsbad, J. Jervell, J. Mustonen (2004)
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.The New England journal of medicine, 351 19
M. Zeisberg, E. Neilson (2010)
Mechanisms of tubulointerstitial fibrosis.Journal of the American Society of Nephrology : JASN, 21 11
G. Maschio, D. Alberti, G. Janin, F. Locatelli, J. Mann, M. Motolese, C. Ponticelli, E. Ritz, P. Zucchelli (1996)
Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal InsufficiencyThe New England Journal of Medicine, 334
H. Knoche (1979)
Lehrbuch der Histologie
J. Wright, G. Bakris, T. Greene, L. Agodoa, L. Appel, J. Charleston, D. Cheek, Janice Douglas-Baltimore, J. Gassman, R. Glassock, L. Hebert, K. Jamerson, J. Lewis, R. Phillips, R. Toto, J. Middleton, S. Rostand (2002)
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.JAMA, 288 19
E. Gagliardini, S. Conti, A. Benigni, G. Remuzzi, A. Remuzzi (2010)
Imaging of the porous ultrastructure of the glomerular epithelial filtration slit.Journal of the American Society of Nephrology : JASN, 21 12
Piero Ruggenenti, A. Perna, Lidia Mosconi, M. Matalone, Roberto Pisoni, Flavio Gaspari, Giuseppe Remuzzi (1997)
Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).Kidney international. Supplement, 63
A. Ble, M. Mosca, Giorgio Loreto, A. Guglielmotti, G. Biondi, S. Bombardieri, G. Remuzzi, P. Ruggenenti (2011)
Antiproteinuric Effect of Chemokine C-C Motif Ligand 2 Inhibition in Subjects with Acute Proliferative Lupus NephritisAmerican Journal of Nephrology, 34
W. Yeo, L. Ramsay, P. Jackson (1992)
Renal protective effect of enalapril in diabetic nephropathy.British Medical Journal, 304
Sabrina Sandhu, N. Wiebe, L. Fried, M. Tonelli (2006)
Statins for improving renal outcomes: a meta-analysis.Journal of the American Society of Nephrology : JASN, 17 7
K. Sharma, J. Ix, A. Mathew, Monique Cho, A. Pflueger, S. Dunn, Barbara Francos, Shoba Sharma, B. Falkner, T. McGowan, M. Donohue, Satish RamachandraRao, R. Xu, F. Fervenza, J. Kopp (2011)
Pirfenidone for diabetic nephropathy.Journal of the American Society of Nephrology : JASN, 22 6
R. Garrick (2011)
Bardoxolone Methyl and Kidney Function in CKD with Type 2 DiabetesYearbook of Medicine, 2011
A. Remuzzi, E. Gagliardini, F. Sangalli, M. Bonomelli, M. Piccinelli, A. Benigni, G. Remuzzi (2006)
ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease.Kidney international, 69 7
G. Becker, T. Hewitson, A. Chrysostomou (2009)
Aldosterone in clinical nephrology--old hormone, new questions.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 24 8
P. Ruggenenti, G. Remuzzi (2009)
Proteinuria: Is the ONTARGET renal substudy actually off target?Nature Reviews Nephrology, 5
P. Ruggenenti, A. Perna, Giulia Gherardi, R. Benini, G. Remuzzi (2000)
Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.American journal of kidney diseases : the official journal of the National Kidney Foundation, 35 6
C. Zoccali, P. Ruggenenti, A. Perna, D. Leonardis, R. Tripepi, G. Tripepi, F. Mallamaci, G. Remuzzi (2011)
Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition.Journal of the American Society of Nephrology : JASN, 22 10
G. Remuzzi, A. Benigni, A. Remuzzi (2006)
Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes.The Journal of clinical investigation, 116 2
(2012)
ALTITUDE study of aliskiren terminated early by Novartis
P. Ruggenenti, A. Perna, G. Loriga, M. Ganeva, B. Ene-Iordache, Marta Turturro, M. Lesti, E. Perticucci, I. Chakarski, D. Leonardis, G. Garini, A. Sessa, C. Basile, M. Alpa, R. Scanziani, G. Sorba, Carmine Zoccali, G. Remuzzi (2005)
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trialThe Lancet, 365
P. Ruggenenti, P. Cravedi, M. Sghirlanzoni, E. Gagliardini, S. Conti, F. Gaspari, G. Marchetti, M. Abbate, G. Remuzzi (2008)
Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy.Clinical journal of the American Society of Nephrology : CJASN, 3 6
J. Mann, R. Schmieder, M. McQueen, L. Dyal, H. Schumacher, J. Pogue, Xingyu Wang, A. Maggioni, A. Budaj, S. Chaithiraphan, K. Dickstein, M. Keltai, K. Metsärinne, A. Oto, A. Parkhomenko, L. Piegas, T. Svendsen, K. Teo, S. Yusuf (2008)
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trialThe Lancet, 372
Fioretto (1998)
Reversal of lesions of diabetic nephropathy after pancreas transplantation.N Engl J Med, 339
A. Benigni, E. Gagliardini, G. Remuzzi (2004)
Changes in glomerular perm-selectivity induced by angiotensin II imply podocyte dysfunction and slit diaphragm protein rearrangement.Seminars in nephrology, 24 2
P. Ruggenenti, A. Perna, R. Benini, T. Bertani, Carmine Zoccali, Q. Maggiore, M. Salvadori, G. Remuzzi (1999)
In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia.Journal of the American Society of Nephrology : JASN, 10 5
R. Zatz, T. Meyer, H. Rennke, B. Brenner (1985)
Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy.Proceedings of the National Academy of Sciences of the United States of America, 82 17
Remission Force (2011)
The Remission Clinic approach to halt the progression of kidney disease.Journal of nephrology, 24 3
P. Cravedi, N. Perico, G. Remuzzi (2010)
Non-immune interventions to protect kidney allografts in the long term.Kidney international. Supplement, 119
(1997)
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathyThe Lancet, 349
P. Cravedi, P. Ruggenenti, G. Remuzzi (2010)
Which antihypertensive drugs are the most nephroprotective and why?Expert Opinion on Pharmacotherapy, 11
M. Pedrini, A. Levey, J. Lau, T. Chalmers, Ping Wang (1996)
The Effect of Dietary Protein Restriction on the Progression of Diabetic and Nondiabetic Renal DiseasesAnnals of Internal Medicine, 124
P. Fioretto, M. Steffes, D. Sutherland, F. Goetz, M. Mauer (1998)
Reversal of lesions of diabetic nephropathy after pancreas transplantation.The New England journal of medicine, 339 2
L. Robertson, N. Waugh, A. Robertson (2007)
Protein restriction for diabetic renal disease.The Cochrane database of systematic reviews, 4
F. Volhard, T. Fahr
Die Brightsche Nierenkrankheit: Klinik, Pathologie und Atlas
Irene Meer, P. Cravedi, G. Remuzzi (2010)
The role of renin angiotensin system inhibition in kidney repairFibrogenesis & Tissue Repair, 3
S. Na, J. Sung, Jae-Hyun Chang, Sejoong Kim, H. Lee, Y. Park, Wookyung Chung, K. Oh, J. Jung (2011)
Chronic Kidney Disease in Cancer Patients: An Independent Predictor of Cancer-Specific MortalityAmerican Journal of Nephrology, 33
J. Peterson, S. Adler, J. Burkart, T. Greene, L. Hebert, L. Hunsicker, A. King, S. Klahr, S. Massry, J. Seifter, Modification (MDRD)Study (1995)
Blood Pressure Control, Proteinuria, and the Progression of Renal DiseaseAnnals of Internal Medicine, 123
R. Garrick (2010)
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney DiseaseYearbook of Medicine, 2010
S. Yusuf, P. Pais, R. Afzal, D. Xavier, K. Teo, J. Eikelboom, A. Sigamani, V. Mohan, R. Gupta, N. Thomas (2009)
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trialThe Lancet, 373
F. Hou, Xun Zhang, G. Zhang, D. Xie, Ping-yan Chen, Wei Zhang, Jian-ping Jiang, M. Liang, G. Wang, Zheng-rong Liu, Ren Geng (2006)
Efficacy and safety of benazepril for advanced chronic renal insufficiency.The New England journal of medicine, 354 2
D. Schlondorff (2008)
Overview of factors contributing to the pathophysiology of progressive renal disease.Kidney international, 74 7
R. Campbell, F. Sangalli, E. Perticucci, C. Aros, C. Viscarra, A. Perna, A. Remuzzi, F. Bertocchi, L. Fagiani, G. Remuzzi, P. Ruggenenti (2003)
Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.Kidney international, 63 3
R. Platt (1952)
Structural and Functional Adaptation in Renal Failure*British Medical Journal, 1
G. Remuzzi, P. Ruggenenti, A. Perna, B. Dimitrov, D. Zeeuw, D. Hille, S. Shahinfar, G. Carides, B. Brenner (2004)
Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.Journal of the American Society of Nephrology : JASN, 15 12
Ashutosh Mahajan, Ashutosh Mahajan, J. Simoni, S. Sheather, Kristine Broglio, Kristine Broglio, M. Rajab, D. Wesson, D. Wesson (2010)
Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy.Kidney international, 78 3
C. Adarkwah, A. Gandjour, Maren Akkerman, S. Evers (2011)
Cost-Effectiveness of Angiotensin-Converting Enzyme Inhibitors for the Prevention of Diabetic Nephropathy in The Netherlands – A Markov ModelPLoS ONE, 6
S. Anderson, B. Brenner (1989)
Progressive renal disease: a disorder of adaptation.The Quarterly journal of medicine, 70 263
P. Ruggenenti, A. Perna, G. Remuzzi (2001)
ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy.Journal of the American Society of Nephrology : JASN, 12 12
R. Lindeman, J. Tobin, N. Shock (1985)
Longitudinal Studies on the Rate of Decline in Renal Function with AgeJournal of the American Geriatrics Society, 33
S. Verma, M. Strauss (2004)
Angiotensin receptor blockers and myocardial infarctionBMJ : British Medical Journal, 329
Aj Apperloo, D. Dezeeuw, P. Dejong (1994)
Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease.Kidney international. Supplement, 45
Curt Wiederhielm, J. Woodbury, Samuel Kirk, Robert Rushmer (1964)
PULSATILE PRESSURES IN THE MICROCIRCULATION OF FROG'S MESENTERY.The American journal of physiology, 207
C. Zoja, D. Corna, D. Camozzi, D. Cattaneo, Daniela Rottoli, Cristian Batani, Cristina Zanchi, M. Abbate, G. Remuzzi (2002)
How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach.Journal of the American Society of Nephrology : JASN, 13 12
A. Go, G. Chertow, Dongjie Fan, C. McCulloch, Chi-yuan Hsu (2004)
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.The New England journal of medicine, 351 13
L. Tylicki, P. Rutkowski, M. Renke, Wojciech Larczyński, E. Aleksandrowicz, W. Lysiak-Szydlowska, B. Rutkowski (2008)
Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.American journal of kidney diseases : the official journal of the National Kidney Foundation, 52 3
H. Trimarchi, A. Muryan, Mariana Dicugno, P. Young, M. Forrester, F. Lombi, V. Pomeranz, R. Iriarte, M. Raña, M. Alonso (2011)
Proteinuria: an ignored marker of inflammation and cardiovascular disease in chronic hemodialysisInternational Journal of Nephrology and Renovascular Disease, 5
R. Glassock, C. Winearls (2009)
Ageing and the glomerular filtration rate: truths and consequences.Transactions of the American Clinical and Climatological Association, 120
Jeffrey Turner, C. Bauer, M. Abramowitz, M. Melamed, T. Hostetter (2012)
Treatment of chronic kidney disease.Kidney international, 81 4
E. Lewis, L. Hunsicker, R. Bain, R. Rohde (1993)
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.The New England journal of medicine, 329 20
S. Vegter, A. Perna, M. Postma, G. Navis, G. Remuzzi, P. Ruggenenti (2012)
Sodium intake, ACE inhibition, and progression to ESRD.Journal of the American Society of Nephrology : JASN, 23 1
Youhua Liu (2010)
New Insights into Epithelial-Mesenchymal Transition in Kidney Fibrosis
W. Elliott (2010)
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trialYearbook of Cardiology, 2010
(2010)
Effects of MCP-1 inhibition by bindarit therapy in type 2 diabetes subjects with micro- or macro-albuminuria
S. Anderson, H. Rennke, B. Brenner (1986)
Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.The Journal of clinical investigation, 77 6
A. Fournier, J. Lalau (1994)
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.The New England journal of medicine, 330 13
P. Ruggenenti, B. Brenner, G. Remuzzi (2001)
Remission Achieved in Chronic Nephropathy by a Multidrug Approach Targeted at Urinary Protein ExcretionNephron, 88
C. Zoja, D. Corna, Giuditta Benedetti, M. Morigi, R. Donadelli, A. Guglielmotti, M. Pinza, T. Bertani, G. Remuzzi (1998)
Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease.Kidney international, 53 3
G. Remuzzi, T. Bertani (1998)
Pathophysiology of progressive nephropathies.The New England journal of medicine, 339 20
C. Baigent, M. Landray, C. Reith, J. Emberson, D. Wheeler, C. Tomson, C. Wanner, V. Krane, A. Cass, J. Craig, B. Neal, Lixin Jiang, L. Hooi, A. Levin, L. Agodoa, M. Gaziano, B. Kasiske, R. Walker, Z. Massy, B. Feldt-Rasmussen, U. Krairittichai, V. Ophascharoensuk, B. Fellström, H. Holdaas, V. Tesar, A. Więcek, D. Grobbee, D. Zeeuw, C. Grönhagen‐Riska, T. Dasgupta, D. Lewis, W. Herrington, M. Mafham, W. Majoni, K. Wallendszus, R. Grimm, T. Pedersen, J. Tobert, J. Armitage, A. Baxter, C. Bray, Yiping Chen, Zhengming Chen, M. Hill, C. Knott, S. Parish, D. Simpson, P. Sleight, A. Young, R. Collins (2011)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialLancet, 377
David Johnson, H. Saunders, R. Baxter, M. Field, C. Pollock (1998)
Paracrine stimulation of human renal fibroblasts by proximal tubule cells.Kidney international, 54 3
Monique Cho, David Smith, M. Branton, S. Penzak, J. Kopp (2007)
Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis.Clinical journal of the American Society of Nephrology : CJASN, 2 5
A. Levey, R. Atkins, J. Coresh, E. Cohen, A. Collins, K. Eckardt, M. Nahas, B. Jaber, M. Jadoul, A. Levin, N. Powe, J. Rossert, D. Wheeler, N. Lameire, G. Eknoyan (2007)
Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes.Kidney international, 72 3
M. Epstein (2009)
Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney diseaseNature Clinical Practice Nephrology, 5
P. Ruggenenti, A. Fassi, Aneliya Ilieva, I. Iliev, C. Chiurchiu, N. Rubis, Giulia Gherardi, B. Ene-Iordache, F. Gaspari, A. Perna, P. Cravedi, A. Bossi, R. Trevisan, N. Motterlini, G. Remuzzi (2011)
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trialJournal of Hypertension, 29
Transforming Growth Factor- (cid:1) 1 Is Up-Regulated by Podocytes in Response to Excess Intraglomerular Passage of Proteins A Central Pathway in Progressive Glomerulosclerosis
M. Taal, Barry Brenner (2000)
Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists.Kidney international, 57 5
G. Gambaro, I. Kinalska, A. Okša, P. Pont'uch, M. Hertlová, J. Olšovský, J. Manitius, D. Fedele, S. Czekalski, J. Perušičová, J. Škrha, J. Tatoň, W. Grzeszczak, G. Crepaldi (2002)
Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial.Journal of the American Society of Nephrology : JASN, 13 6
J. Peterson, S. Adler, J. Burkart, T. Greene, L. Hebert, L. Hunsicker, A. King, S. Klahr, S. Massry, J. Seifter (1995)
Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study.Annals of internal medicine, 123 10
R. Durvasula, A. Petermann, K. Hiromura, M. Blonski, J. Pippin, P. Mundel, R. Pichler, Siân Griffin, W. Couser, S. Shankland (2004)
Activation of a local tissue angiotensin system in podocytes by mechanical strain.Kidney international, 65 1
G. Remuzzi, T. Bertani (1990)
Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?Kidney international, 38 3
J. Oliver, M. Moses, M. Macdowell, Y. Lee (1954)
CELLULAR MECHANISMS OF PROTEIN METABOLISM IN THE NEPHRONThe Journal of Experimental Medicine, 99
P. Ruggenenti, A. Perna, G. Remuzzi (2003)
Retarding progression of chronic renal disease: the neglected issue of residual proteinuria.Kidney international, 63 6
Ibrahim (1997)
Role of the renin-angiotensin-aldosterone system in the progression of renal disease: A critical review.Semin Nephrol, 17
A. Remuzzi, Stefania Puntorieri, C. Battaglia, T. Bertani, G. Remuzzi (1990)
Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat.The Journal of clinical investigation, 85 2
Ho-Jung Kim, J. Ryu, Sang-Woong Han, Ile-Kyu Park, S. Paik, Moon-Hyang Park, D. Paik, Ho-Sam Chung, S. Kim, Jong Lee (2004)
Combined Therapy of Cilazapril and Losartan Has No Additive Effects in Ameliorating Adriamycin-Induced GlomerulopathyNephron Physiology, 97
S. Klahr (1989)
The modification of diet in renal disease study.The New England journal of medicine, 320 13
Ashish Upadhyay, A. Earley, Shana Haynes, K. Uhlig (2012)
Systematic Review: Blood Pressure Target in Chronic Kidney Disease and Proteinuria as an Effect ModifierYearbook of Cardiology, 2012
R. Platt (1936)
The Renal Function in Disease *British Medical Journal, 1
P. Ruggenenti, A. Fassi, Anelja Ilieva, Simona Bruno, I. Iliev, Varusca Brusegan, N. Rubis, Giulia Gherardi, Federica Arnoldi, M. Ganeva, B. Ene-Iordache, F. Gaspari, A. Perna, A. Bossi, R. Trevisan, A. Dodesini, G. Remuzzi (2004)
Preventing microalbuminuria in type 2 diabetes.The New England journal of medicine, 351 19
H. Ibrahim, M. Rosenberg, T. Hostetter (1998)
Role of Renin-Angiotensin-Aldosterone System in the Progression of Renal Disease: A Critical ReviewThe Journal of Urology, 160
Journal of the American Society of Nephrology – Unpaywall
Published: Dec 1, 2012
Access the full text.
Sign up today, get DeepDyve free for 14 days.